Sri Lanka Trilingual Labelling and PIL in Sinhala Tamil English

1. Key takeaways

Sri Lanka’s labelling rules can be summarised in three layers: (1) all products must submit primary and secondary labels, which are reviewed as part of the registration dossier; (2) for professional-use Class IIa, IIb, and III devices, English-language labels are generally acceptable; (3) for home-use devices intended for direct use by patients, the patient information leaflet (PIL) must be provided simultaneously in three official languages — English, Sinhala, and Tamil. The MAH must ensure that the primary and secondary labels remain compliant with NMRA requirements throughout the product lifecycle. The three layers work in opposite directions on cost: the first layer applies to every product without exception, the second relaxes the language burden for professional products, and the third tightens it sharply for the specific subset of devices that patients operate themselves. Mapping a portfolio against the three layers early — product by product, against the home-use definition rather than against marketing intent — is the foundation of any credible labelling budget for the Sri Lankan market.

• Primary and secondary labels are mandatory for all products and are reviewed as part of the initial registration documents (NMRA medical device page / industry compilation).
• English labels are generally accepted for professional-use Class IIa, IIb, and III devices.
• Home-use devices for direct patient operation require a trilingual PIL in English, Sinhala, and Tamil.
• The MAH carries the ongoing responsibility for label compliance across the entire product lifecycle.

2. Legal basis

The labelling requirements below are compiled from the NMRA medical device page together with industry compilation, and are therefore marked accordingly. The label element list is extensive, and each element is checked against the submitted primary and secondary labels during dossier review.

3. Expert insights

Insight one: the trilingual requirement targets the PIL, not all label content. The wording of the rule is that the relevant patient information leaflet (PIL) must be provided in three official languages. Interpreting it as a requirement that all printed materials be trilingual will make translation costs spiral out of control. The distinction matters commercially: only the patient-facing leaflet of qualifying home-use devices needs Sinhala and Tamil versions, while the professional labelling can remain in English within the conditions described above. Reading the rule precisely, rather than broadly, keeps the translation scope proportional to the obligation.

Insight two: the trilingual requirement for home-use devices is hard, not discretionary. The examples given explicitly include blood glucose meters, hearing aids, spacer devices, and nebulisers — products that patients operate themselves. For such products entering Sri Lanka, the trilingual PIL is an unavoidable cost item. These are precisely the product types with the largest patient volumes, which amplifies the impact: the requirement attaches to the categories most likely to be commercial priorities. Budgeting for qualified Sinhala and Tamil translations, and for their maintenance whenever the source PIL changes, belongs in the entry plan rather than in the contingency column.

Insight three: transposing labels directly from the European Union or the United States creates problems. The rules note explicitly that the mandatory labelling elements of the EU MDR overlap heavily with NMRA requirements but are not fully identical, and parts that directly cite the CE mark or EU-specific regulatory symbols need adaptation for the Sri Lankan market version. A label that is fully compliant in Europe can therefore still be non-compliant in Colombo, not because of missing content but because of content that does not belong. This is the least intuitive of the three layers for experienced exporters, and the one most often caught late, because the offending elements sit on artwork that everyone on the project has seen a hundred times and no longer reads critically.

A closing note on the element list: the requirement to carry the Sri Lanka registration number only after registration means labels must be designed with that field present but empty — or managed through a controlled post-registration revision. Either approach should be chosen deliberately, since an uncontrolled artwork change after approval can otherwise create a mismatch between the approved dossier and the printed material in the market.

4. Practical recommendations

• GRZAN executes a three-pass check for label compliance: pass one compares the labels against the NMRA element list item by item to find gaps; pass two verifies the completeness and consistency of the trilingual PIL (especially numbers, units, and warning statements); pass three removes label statements that directly cite the CE mark or EU-specific symbols and replaces them with a version fitting the Sri Lankan market.
• The third pass is the most easily overlooked, yet it is the most common reason for returns at intake.
• Reserve a position on the label for the Sri Lanka registration number, which is added only after registration is granted.
• Re-run the three-pass check whenever the source artwork changes, since upstream label revisions silently reintroduce removed elements.

5. Verification checklist

• □ Primary and secondary labels compiled and included in the dossier
• □ Label contains product name, model / catalogue number, manufacturer name and address
• □ Label contains intended use, warnings and precautions
• □ Label contains sterilisation method, expiry date, batch number, storage conditions, country of origin
• □ Home-use devices have a trilingual PIL in English / Sinhala / Tamil
• □ Statements directly citing the CE mark and EU-specific symbols removed or replaced
• □ Position reserved for the Sri Lanka registration number (added after registration)

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Sri Lanka. Our team prepares dossiers to NMRA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com